Physician profile
Albert K Bui
NPI 1548536188
$1,773.68
in general payments reported to CMS, 2019-2025
14 companies · $1,122 in 2025
The $1,122 reported for 2025 was more than what 90% of Geriatric Medicine (Internal Medicine) providers received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.17 · 2024: $640 · 2025: $1,122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,763.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,762.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $593.57 | 2024-2025 | Evenity, Prolia, Prolia |
| Astrazeneca Pharmaceuticals LP | $253.46 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $156.93 | 2024-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $148.80 | 2024-2025 | Shingrix, Arexvy, Penmenvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $129.91 | 2024-2025 | Jardiance |
| Lilly USA, LLC | $126.42 | 2024-2025 | Zepbound, Mounjaro |
| Novartis Pharmaceuticals Corporation | $89.00 | 2025 | |
| Radius Health, INC. | $73.87 | 2025 | Tymlos |
| Merck Sharp & Dohme LLC | $55.53 | 2024-2025 | Capvaxive, Gardasil 9, M-M-R II |
| Gilead Sciences, INC. | $45.45 | 2025 | |
| Pfizer INC. | $45.00 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $19.27 | 2025 | Zoryve |
| Esperion Therapeutics, INC. | $19.11 | 2025 | Nexletol |
| Dexcom, INC. | $17.36 | 2025 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Bui listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.